Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Joshua Hopkins

Physician Assistant, Medical Welch, WV Physician Assistant

NPI 1821437617 CMS profile 219383

19771 Coal Heritage Road Suite 102, Welch, WV 24801

Open in the dashboard

General payments

$3,835

232 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joshua Hopkins of Welch, WV is reported in the CMS Open Payments database as having received $3,835 across 232 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $735 41
2024 General $878 52
2023 General $607 37
2022 General $827 50
2021 General $789 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Hopkins
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Joshua Hopkins were reported at $735. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Joshua Hopkins Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $789 $156 $41–$563 $132
2022 $827 $185 $55–$649 $149
2023 $607 $199 $58–$717 $160
2024 $878 $206 $62–$740 $164
2025 $735 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $484 29 payments
  2. GlaxoSmithKline, LLC. $484 34 payments
  3. Abbott Laboratories $429 21 payments
  4. AbbVie, Inc. $383 23 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $285 18 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $269 18 payments
  7. AstraZeneca Pharmaceuticals LP $257 15 payments
  8. Lilly USA, LLC $182 11 payments
  9. Pfizer Inc. $148 11 payments
  10. Amgen Inc. $128 8 payments
  11. Other $787 44 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,824 231 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $484 34 payments
  2. Ozempic $421 25 payments
  3. FreeStyle Libre 2 $412 20 payments
  4. RYBELSUS $404 24 payments
  5. XIFAXAN $269 18 payments
  6. SPIRIVA RESPIMAT $186 14 payments
  7. VRAYLAR $140 9 payments
  8. JARDIANCE $135 7 payments
  9. FARXIGA $132 8 payments
  10. QULIPTA $131 8 payments
  11. Other $2,344 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 213 drugs

Part D claims

16,378

Median for Physician Assistant: 241

Drug cost

$1,151,833

Median for Physician Assistant: $4,110

Branded share of claims

24.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 139 $175,711
Mounjaro Tirzepatide Brand 124 $134,401
Farxiga Dapagliflozin Propanediol Brand 87 $77,339
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 91 $68,725
Eliquis Apixaban Brand 79 $62,625
Trulicity Dulaglutide Brand 59 $60,744
Linzess Linaclotide Brand 70 $49,092
Rybelsus Semaglutide Brand 33 $47,941
Januvia Sitagliptin Phosphate Brand 38 $31,218
Xarelto Rivaroxaban Brand 36 $30,137

The 10 drugs with the highest cost, of 213 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $197
$197 91 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $90
$90 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $73
$73 — —
RYBELSUS
  • Novo Nordisk Inc $72
$72 33 —
Ozempic
  • Novo Nordisk Inc $72
$72 139 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

232 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record